title: Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine?
authors.forename: Klaus
authors.initials: K
authors.lastname: Larsen
authors.forename: Nete
authors.initials: N
authors.lastname: Hornnes
authors.forename: Gudrun
authors.initials: G
authors.lastname: Boysen
mesh_terms: D000179:Acrylates / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009568:Nitrendipine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000401:mortality* / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D000179:Acrylates; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan; D009568:Nitrendipine